Ribo Appoints CMO and CBO to Empower Global R&D and Partnerships
March 26, 2026 – Suzhou Ribo Life Science Co., Ltd. ("Ribo" or "the Company", Hong Kong Stock Exchange code: 6938) today announced two key executive appointments: as approved by the Board of Directors, Dr. Anders Gabrielsen, former Vice President and Global Head of Clinical Development, has been appointed Chief Medical Officer (CMO), and will oversee the clinical development strategy, medical affairs and regulatory compliance to ensuring medical excellence and regulatory adherence throughout Ribo’s drug pipeline development process; Dr. John Taylor, former Vice President and Global Head of Business Development, has been appointed Chief Business Officer (CBO), and will lead the Ribo’s BD transactions, licensing collaborations, and strategic investments, continuously creating values and enhancing Ribo’s global competitiveness.
Dr. Anders Gabrielsen is an accomplished physician‑scientist with more than 20 years of experience in cardiovascular, renal, and metabolic therapeutics. He trained and practiced as a cardiologist and internist at the Karolinska Institute and Karolinska University Hospital in Sweden, specializing in heart failure. Before joining Ribo, Dr. Gabrielsen held physician‑scientist roles in clinical development and medical affairs at leading multinational companies including Bayer, Novartis, and AstraZeneca. In these positions, he served in key leadership and executive capacities across core clinical and medical teams, contributing to all aspects of cardiology and internal medicine with a strong focus on translational and clinical cardiovascular science and medical implementation. Dr. Gabrielsen earned his M.D. from the University of Copenhagen, completed clinical training and cardiovascular research, and undertook a Marie Curie postdoctoral research fellowship in myocardial gene expression at the Karolinska Institute. He later received a Doctor of Medical Sciences (DMSc) degree from the University of Copenhagen.
Dr. John Taylor brings more than 20 years of experience in the global biopharmaceutical industry, with deep expertise spanning foundational scientific research through corporate business development. Before joining Ribo, Dr. Taylor worked in global research and development at Pfizer Inc., where he was responsible for driving innovative R&D initiatives and leading key projects. He later held a series of roles at AstraZeneca PLC, including Head of Biology for Respiratory and Inflammation, as well as leadership positions in search and evaluation and in business development, where he contributed to both scientific assessment and transaction execution. Dr. Taylor earned his Ph.D. in Biochemistry from the University of Bristol in the United Kingdom, focusing on DNA–protein recognition, and subsequently conducted postdoctoral research on DNA mismatch repair at Duke University in the United States.
Dr. Zicai Liang, Founding Chairman & CEO of Ribo, commented: “With continuous breakthroughs in extrahepatic delivery technologies lately, Ribo is advancing toward its goal of becoming a global leader in siRNA drug development with unprecedented depth and breadth. The two executive appointments will significantly drive the implementation of our core strategies—international clinical development and global business partnerships. We look forward to writing a new chapter for Ribo together with these two highly experienced industry leaders, accelerating our drug development and expanding international collaborations, and bringing Ribo’s innovative siRNA therapies to patients worldwide as soon as possible.”